| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Hepsera (TN) | ||||||||||
| Product | HEPSERA (Gilead Sciences) | ||||||||||
| Generic | ADEFOVIR DIPIVOXIL (Apotex Corp.), ADEFOVIR DIPIVOXIL (Sigmapharm Laboratories) | ||||||||||
| Formula | C20H32N5O8P | ||||||||||
| Exact mass | 501.1989 | ||||||||||
| Mol weight | 501.4705 | ||||||||||
| Structure |  | ||||||||||
| Class | Antiviral DG01890 Nucleoside reverse transcriptase inhibitor (NRTI) | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antiviral, Reverse transcriptase inhibitor | ||||||||||
| Disease | Hepatitis B [DS:H00412] | ||||||||||
| Comment | Active form of prodrug: Adefovir [DR:D02768] | ||||||||||
| Target | HBV reverse transcriptase [KO:K21037] | ||||||||||
| Pathway |
| ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AF Nucleoside and nucleotide reverse transcriptase inhibitors J05AF08 Adefovir dipivoxil D01655 Adefovir dipivoxil (USAN) <JP/US> USP drug classification [BR:br08302] Antivirals Anti-hepatitis B (HBV) Agents Adefovir D01655 Adefovir dipivoxil (USAN) Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D01655 Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN) Drug groups [BR:br08330] Antiviral DG01890 Nucleoside reverse transcriptase inhibitor (NRTI) DG01224 Adefovir D01655 Adefovir dipivoxil Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor HBV reverse transcriptase inhibitor D01655 Adefovir dipivoxil (USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01655 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D01655 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D01655 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01655 Prodrugs [br08324.html] D01655 Drug groups [BR:br08330] Antiviral DG01890 Nucleoside reverse transcriptase inhibitor (NRTI) DG01224 Adefovir Antimicrobials abbreviations [BR:br08327] Antivirals Genome replication inhibitor HBV reverse transcriptase inhibitor DG01224 Adefovir | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 34 1 C8y C 29.9600 -16.0300 2 C8y C 29.9600 -14.5600 3 N4y N 28.6300 -16.4500 4 N5x N 31.1500 -16.6600 5 N5x N 28.6300 -14.1400 6 C8y C 31.1500 -13.9300 7 C8x C 27.7900 -15.3300 8 C8x C 32.3400 -16.0300 9 N5x N 32.3400 -14.5600 10 N1a N 31.1500 -12.5300 11 C1b C 28.6300 -17.8500 12 C1b C 27.3700 -18.5500 13 O2a O 26.1800 -17.8500 14 C1b C 24.9200 -18.5500 15 P1b P 23.7300 -17.8500 16 O2b O 22.5400 -17.1500 17 O2b O 23.0300 -19.0400 18 O3b O 24.4300 -16.6600 19 C1b C 22.5400 -15.7500 20 O7a O 21.3500 -15.0500 21 C7a C 20.1600 -15.7500 22 C1d C 18.9700 -15.0500 23 C1b C 23.0300 -20.4400 24 O7a O 21.8092 -21.1430 25 O6a O 20.1600 -17.1500 26 C1a C 17.7800 -14.3500 27 C1a C 19.6700 -13.7900 28 C1a C 18.2700 -16.2400 29 C7a C 20.6459 -20.4401 30 C1d C 19.4251 -21.1431 31 O6a O 20.6335 -19.0384 32 C1a C 18.2043 -21.8461 33 C1a C 20.1281 -22.3639 34 C1a C 18.7221 -19.9223 BOND 35 1 2 5 1 2 2 6 1 3 3 7 1 4 4 8 2 5 6 9 2 6 5 7 2 7 8 9 1 8 1 2 2 9 1 3 1 10 1 4 1 11 6 10 1 12 3 11 1 13 11 12 1 14 12 13 1 15 13 14 1 16 14 15 1 17 15 16 1 18 15 17 1 19 15 18 2 20 16 19 1 21 19 20 1 22 20 21 1 23 21 22 1 24 17 23 1 25 23 24 1 26 21 25 2 27 22 26 1 28 22 27 1 29 22 28 1 30 24 29 1 31 29 30 1 32 29 31 2 33 30 32 1 34 30 33 1 35 30 34 1 |